CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Valeritas Holdings, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Valeritas Holdings, Inc.
750 US Highway 202
Suite 600
Phone: (908) 927-9920p:908 927-9920 Bridgewater, NJ  08807-2597  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 4/2/2020.
This company ceased filing statements with the SEC on 4/3/2020.
The Company’s Plan of Liquidation went into effect on 6/30/2020
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Valeritas Holdings, Inc. is a commercial-stage medical technology company. The Company’s product, V-Go Wearable Insulin Delivery device (V-Go), is a wearable, basal-bolus insulin delivery device for adult patients requiring insulin that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. V-Go is a small wearable and completely disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. It has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201912/31/2018YesYesYes-Yes

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
3842 Orthopedic, prosthetic, and surgical appliances and supplies

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Peter J.Devlin 51 4/2/2020 4/1/2016
Vice President - Sales Hokan L.Ojert 1/1/2016 1/1/2016
Vice President - Corporate Compliance and Information Systems Scott A.Huie 54 1/1/2018 1/1/2016
Vice President - Research & Development ChrisGregory 3/1/2013 3/1/2013

Business Names
Business Name
CYGM
CYGMD
Valeritas Security Corporation
5 additional Business Names available in full report.

General Information
Outstanding Shares: 8,271,503 (As of 9/30/2019)
Shareholders: 131
Stock Exchange: OTC
Federal Tax Id: 465648907
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023